NCT06941350View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

May 30, 2027

Conditions
Acute Graft-versus-Host Disease
Interventions
BIOLOGICAL

NCR102 injection

Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.

Sponsors
All Listed Sponsors
lead

Nuwacell Biotechnologies Co., Ltd.

INDUSTRY